Does this not get old when everyone is trying to save money in healthcare in every which area?  .  Well one of the 2 companies is getting a new CEO but it’s not Johnson and Johnson. 

Consumers lose as all this gets built into the price.

Will the “Stent Wars” Ever End – We Want to Be Able to Afford them Boston Scientific Files Cross Appeal
Where’s Some of the Focus for Johnson and Johnson Revenue Cycles – “Legally Patented Stent Wars”?

Boston Scientific (NYSE:BSX) took a time-out from the tsuris over CEO Ray Elliott's resignation to crow over a $19.5 million jury award in one of its stent wars with Johnson & Johnson's (NYSE:JNJ) Cordis Corp.

The case is one of two before Judge Susan Robinson of the U.S. District Court for Delaware, who ruled that separate juries would consider the penalty phases back in 2009.

Cordis won its June 2005 lawsuit against Boston Scientific, which accused the Natick, Mass.-based stent pioneer of infringing two of its patents (known as the "Palmaz '762" and "Gray '406" patents) with its Express, Taxus Express and Liberté stents.

Boston Scientific logs a win in stent war with J&J's Cordis | MassDevice - Medical Device Industry News


Post a Comment

Google Analytics Alternative